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During his visit to Florence in 1817 the French author Stendhal experienced sudden palpitations, 
dizziness and confusion on beholding the vast amount of magnificent artwork. This phenomenon was 
later called the Stendhal syndrome. Nowadays, physicians are prone to a certain kind of Stendhal 
syndrome when facing the massive amount of papers being published worldwide. Selection of 
interesting and reliable manuscripts is important, but the true challenge lies in making sense of all 
results, especially when conflicting data emerge. 
The Cochrane Collaboration was founded in 1993 in response to a call from an epidemiologist, Archie 
Cochrane, for up-to-date, systematic reviews or ‘critical summaries’ of all relevant randomized 
controlled trials (RCT) of health care interventions. Using stringent guidelines, the Cochrane 
Collaboration collects data on a specific research topic and establishes whether there is conclusive 
evidence of utility for a treatment or intervention. Cochrane reviews are recognized by many as the 
highest standard in evidence-based health care resources. 
 
In 2007, the first Cochrane review on structured telephone support (STS) or telemonitoring (TM) 
programmes for patients with chronic heart failure (HF) was published, followed by an update in 
2010. [1, 2] The latter identified thirty RCT’s (25 peer reviewed publications and five abstracts), including 
9,806 patients. The main conclusion of this meta-analysis was that patients assigned to TM had lower 
all-cause mortality (RR 0.66, 95% CI 0.54-0.81, p<0.0001) and fewer HF-related hospitalisations (RR 
0.79, 95% CI 0.67-0.94, p 0.008), while the effect of STS was limited to HF-related hospitalisations (RR 
0.77 (95% CI 0.68-0.87), p < 0.0001). Criticisms included the methodological quality of individual 
studies, heterogeneity and potential publication bias.[3, 4] The subsequent publication of several 
large RCT’s with neutral results in the following years resulted in growing uncertainty regarding the 
benefit of STS and TM.[5, 6] Based on these conflicting results, the 2012 ESC guidelines for the 
diagnosis and treatment of acute and chronic HF did not recommended widespread implementation 
of remote monitoring and called for more research.[7] In response to these recommendations from 
3 
 
the ESC, a further update of  the Cochrane review was undertaken and published in the Cochrane 
Library  in October 2015.[8]  
 
The main differences between the 2015 and 2010 versions are: 1) inclusion of 17 new RCT’s (41 in 
total, including 12,947 patients), 2) exclusion of abstracts (only completed studies published in peer-
reviewed journals were eligible), 3) exclusion of the study by Kielbock et al. which was considered by 
some to be a cohort study open to bias rather than an RCT [4, 9], and 4) re-classification of a study 
that used interactive voice response technology as STS instead of TM.[10] The latest update of the 
Cochrane review again demonstrates that, compared to usual care, STS reduces all-cause mortality 
by 13% (95%CI 0.77 to 0.98) and heart failure-related hospitalisations by 15% (95% CI 0.77 to 0.93) 
and that non-invasive TM improves these outcomes by 20% (95% CI 0.68 to 0.94), and 29% (95% CI 
0.60 to 0.83) respectively. These results confirm those reported in the previous Cochrane reviews 
and should encourage readers to put recent studies with a neutral outcome into perspective. More 
recent trials may have increased uncertainty but, overall, the balance of evidence still suggests that 
these interventions do reduce mortality and HF admissions.  
 
In May 2016, the new ESC guidelines on diagnosis and treatment of acute and chronic heart failure 
were published.11 These guidelines include a section on ‘follow-up and monitoring’, stating that 
“numerous prospectively initiated clinical trials (a.o. Tele-HF, TIM-HF, INH, WISH and TEHAF) 
including >3,700 patients have not confirmed clinical benefits of telemedicine in HF”. Surprisingly, 
the recently published Cochrane review comprising data on >12,000 patients and >40 RCT’s is not 
mentioned. Also, the magnitude of benefit of non-invasive TM is similar to that observed with some 
interventions that received Class I or IIa recommendations in the latest ESC guidelines. In our 
opinion, this is an important omission from the current guidelines [11]  considering the esteem in 
which The Cochrane Collaboration is generally held. 
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The reasons for the fog that continues to surround the topic of remote monitoring in HF are multiple 
and include the use of different technologies for different types of patients (stable versus unstable), 
over different periods of time, in a different era (of background treatment) and with different 
comparators (“usual care” sometimes being enhanced to an unusual degree).   
 
Of four different types of noninvasive remote monitoring technologies (STS, TM, videophone, and 
interactive voice response devices) only STS and TM appear effective in reducing the risk of all-cause 
mortality and heart failure–related hospitalizations.[12] The poor compliance associated with use of 
telephone-based interactive voice-response technology in the Tele-HF study is an important reason 
for the neutral result of this trial. [6] WISH, another neutral study, focused solely on weight 
monitoring, a variable that has a low sensitivity for detecting deterioration [13, 14]. Finally, TIM-HF 
was a well-designed and conducted RCT, but focused on stable, well-treated patients with HF who 
had low event rates.[5] Remote monitoring alone has no benefit; it can only improve patient 
outcomes by improving the delivery of interventions that modify outcome, for example ensuring safe 
implementation of target doses of HF medicines. Therefore, it is not surprising that TM has little 
impact on outcome in stable patients already receiving expert treatment. The TEN-HMS study nicely 
demonstrated that TM was associated with higher prescription rates of disease modifying 
medications, which may explain the positive effect on mortality observed in this trial.[15] 
 
The Cochrane review has focused solely on non-invasive remote monitoring of patients with heart 
failure, but other meta-analyses have examined the effects of remote monitoring through cardiac 
implantable electronic devices (CIEDs). Individual studies have yielded conflicting results, but the 
overall conclusion of pooled data suggest that invasive monitoring reduces hospital visits (mainly 
planned visits), with no effect on cardiac hospitalisations and mortality.[16] The accuracy of CIED 
diagnostics in predicting worsening HF is fundamentally limited by the function of the device. 
Monitoring “device diagnostics” allow us to detect device malfunction early, to minimize the risk of 
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inappropriate shocks and to reduce the time to clinical decisions. However, this success has not yet 
been accompanied by a reduction in heart failure events, probably because many other aspects  
of the disease contribute to poor outcome.[17]   
 
To summarize, RCTs of STS and TM in heart failure are not consistently positive but the bulk of 
evidence is in favour of a beneficial effect, both on overall mortality and HF-related hospitalisations. 
This has been shown by several Cochrane reviews, the most recent one being published only one 
year ago. Cochrane Reviews are internationally recognized as high quality work, and should not be 
omitted from current guidelines, especially when they provide interesting information and help to put 
individual trials into perspective. When access to specialist multidisciplinary heart failure programmes 
continues to be limited by barriers created by geography, healthcare systems and funding, it seems 
unwise to ignore evidence for a method of delivering an important clinical service to the most 
disadvantaged HF populations. Globally, many HF patients do not have access to specialized, face-to-
face heart failure care; remote monitoring can help compensate for this.  
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Table 1 
Cochrane review Era Included trials (n) Mortality HF-related hospitalisations 
2007 
   TM 
   STS 
1966-2006 14  
RR 0.62 (0.45-0.85) 
RR 0.85 (0.72-1.01) 
 
RR 0.86 (0.57-1.28) 
RR 0.78 (0.68-0.89) 
2010 
   TM 
   STS 
1966-2008 30  
RR 0.66 (0.54-0.81) 
RR 0.88 (0.76-1.01) 
 
RR 0.79 (0.67–0.94) 
RR 0.77 (0.68–0.87) 
2015 
   TM 
   STS 
1966-2015  41  
RR 0.80 (0.68- 0.94) 
RR 0.87 (0.77- 0.98) 
 
 
RR 0.71 (0.60- 0.83) 
RR 0.85 (0.77 -0.93) 
Table 1. Summary of main characteristics of the Cochrane reviews of 2007, 2010 and 2015 on 
structured telephone support or non-invasive telemonitoring for patients with heart failure. TM = 
telemonitoring; STS = structured telephone support; HF = heart failure; RR = risk ratio. Risk ratios are 
presented with the corresponding confidence interval.  
 
 
 
 
 
